« Back
Home /
Nintedanib

Nintedanib

Item no.	TMO-T1777-500mg
Manufacturer	TargetMol
CASRN	656247-17-5
Amount	500 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mL 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Oncology Reagents & Chemicals Molecules By Organ Colorectal Cancer
Type	Molecules
Specific against	other
Citations	1. Hilberg F, et al. Y Res, 2008, 68(12), 4774-4782.
Smiles	COC(c1cc2c(/C(C(N2)=O)=C(c3ccccc3)/Nc4ccc(N(C(CN5CCN(CC5)C)=O)C)cc4)cc1)=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	BIBF 1120,Intedanib
Shipping Condition	Cool pack
Available
Manufacturer - Targets	VEGFR\|\|\|FLT\|\|\|FGFR\|\|\|PDGFR\|\|\|Src
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	539.62
Description	Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
Pathways	Tyrosine Kinase/Adaptors\|\|\|Angiogenesis
Bioactivity	Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRalpha/beta with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Receptor	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T1777-500mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 500 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question